WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoANTIRETRO-VIRALS - Benefit/Risk balance remains strongly positive for combination antiretroviral therapy
Ver el documentoCYPROTERONE ACETATE & ETHINYL-ESTRADIOL - Update on risk of venous thromboembolism
Ver el documentoDIETHYL-STILBESTROL - Gynaecological and obstetric complications after in utero exposure
Ver el documentoEPHEDRA - Moves to reduce risks of ephedra-containing products
Ver el documentoFLUTICASONE PROPIONATE - Reports of adrenal crisis
Ver el documentoGRAPEFRUIT JUICE - Revised advice from ADRAC
Ver el documentoHORMONE REPLACEMENT THERAPY (HRT) - Risk of dementia
Ver el documentoOMEPRAZOLE, RABEPRAZOLE - Reports of interstitial nephritis
Ver el documentoROFECOXIB, CELECOXIB - Case reports support causal association with liver toxicity
Ver el documentoROSIGLITA-ZONE, PIOGLITAZONE - Adverse reactions update
Ver el documentoSOMATROPIN - Not to be authorized for AIDS-related wasting syndrome
Abrir esta carpeta y ver su contenidoCURRENT CONCERNS
Abrir esta carpeta y ver su contenidoDRUGS OF INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

ANTIRETRO-VIRALS - Benefit/Risk balance remains strongly positive for combination antiretroviral therapy

Europe. The Committee for Proprietary Medicinal Products (CPMP) has issued a public statement that the benefit/risk balance of combination anti-retroviral treatment (CART) remains strongly positive in HIV infected patients. The statement follows an analysis of the results of studies undertaken by various groups to address questions concerning the prevalence and especially, the incidence of long-term cardiovascular and metabolic complications associated with CART. The CPMP holds that the long-term cardiovascular effect of CART has not been conclusively demonstrated and therefore concerns about the risk of cardiovascular disease should not lead to the withholding of CART when indicated for HIV-patients; ongoing studies of long-term cardiovascular complications should be continued for an extended follow-up time, at least till January 2005 to provide more conclusive results.

Reference:
CPMP Public Statement, EMEA/CPMP/2383/03, 25 Apr 2003. Available from URL: http://www.emea.eu.int

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019